17643-24-2

Basic information

• Product Name: 1-AMINO-2-PHENYL-PROPAN-2-OL
• Synonyms: AKOS BB-9873;1-AMINO-2-PHENYL-PROPAN-2-OL;Benzenemethanol, .alpha.-(aminomethyl)-.alpha.-methyl-
• CAS NO: 17643-24-2
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.21
• Product Categories: pharmacetical
• Mol File: 17643-24-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 293.561 °C at 760 mmHg
• Flash Point: 131.341 °C
• Appearance: /
• Density: 1.074 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: 1-AMINO-2-PHENYL-PROPAN-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-AMINO-2-PHENYL-PROPAN-2-OL(17643-24-2)
• EPA Substance Registry System: 1-AMINO-2-PHENYL-PROPAN-2-OL(17643-24-2)

Safety Data

• Hazardous Substances Data: 17643-24-2(Hazardous Substances Data)

Usage

General Description

1-AMINO-2-PHENYL-PROPAN-2-OL, also known as amphetamine, is a psychoactive drug that acts as a central nervous system stimulant. It is a chiral compound, meaning it has two enantiomers with different pharmacological effects. Amphetamine is commonly used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, as well as for weight loss in some cases. It works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which leads to increased alertness, focus, and energy. However, it also has a high potential for abuse and addiction, with prolonged use leading to tolerance and dependence. Adverse effects of amphetamine use may include insomnia, anxiety, and cardiovascular issues, making it a controlled substance in many countries.

InChI:InChI=1/C9H13NO/c1-9(11,7-10)8-5-3-2-4-6-8/h2-6,11H,7,10H2,1H3

Upstream product

• 115051-47-3 2-hydroxy-2-phenyl-propionaldehyde-oxime 
• 15561-33-8 1-chloro-2-phenylpropan-2-ol 
• 98-83-9 isopropenylbenzene 
• 2085-88-3 2-methyl-2-phenyloxirane 
• 2406-22-6 (R)-1-phenyl-1,2-ethanediol 
• 627076-70-4 (R)-2-hydroxy-2-phenylpropyl 4-methylbenzenesulfonate 
• 98-86-2 acetophenone 
• 127462-20-8 2-phenyl-2-trimethylsilyloxypropanenitrile 
• 17643-24-2 (+/-)-1-amino-2-phenylpropan-2-ol 
• 57402-97-8 N-<(trimethylsilyl)methyl>benzaldimine 
• 88626-82-8 C₂₈H₂₇N₃O₃Si 
• 26067-95-8 1-(Diphenylmethylenamino)-phenyl-2-propanol 
• 7737-17-9 1-aminopropan-2-one hydrochloride 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1383925-60-7 (S)-(-)-5-methyl-5-phenyl-2-(pyrid-2-yl)-1,3-oxazoline 
• 17643-24-2 (S)-1-amino-2-phenylpropan-2-ol 
• 17643-24-2 (R)-1-amino-2-phenylpropan-2-ol 
• 1401003-93-7 tert-butyl (2-hydroxy-2-phenylpropyl)carbamate 
• 1414772-11-4 1-{[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino}-2-phenylpropan-2-ol 
• 52553-03-4 5-methyl-5-phenyloxazolidin-2-one 
• 103-79-7 1-phenyl-acetone 
• 124580-22-9 (2R,3R,4S,5R)-2-[6-Amino-2-((R)-2-hydroxy-2-phenyl-propylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol 
• 124580-25-2 (2R,3R,4S,5R)-2-[6-Amino-2-((S)-2-hydroxy-2-phenyl-propylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol 

Relevant articles and documents

Absolute stereochemical determination of 1,2-diols via complexation with dinaphthyl borinic acid

Rapid derivatization of chiral 1,2-diols with dinaphthyl borinic acid (DBA) leads to a cyclic boronate, enabling the absolute stereochemical prediction via exciton-coupled circular dichroic (ECCD) of the naphthyl groups. Aryl- and alkyl-substituted 1,2-diols derivatized with DBA yield a predictable ECCD, which is also in agreement with theoretical predictions derived from computationally minimized structures.

Direct catalytic synthesis of unprotected 2-amino-1-phenylethanols from alkenes by using iron(II) phthalocyanine

Aryl-substituted amino alcohols are privileged scaffolds in medicinal chemistry and natural products. Herein, we report that an exceptionally simple and inexpensive FeII complex efficiently catalyzes the direct transformation of simple alkenes into unprotected amino alcohols in good yield and perfect regioselectivity. This new catalytic method was applied in the expedient synthesis of bioactive molecules and could be extended to aminoetherification.

GSK-3BETA INHIBITOR

For the purpose of providing a GSK-3β inhibitor containing a 2-aminopyridine compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (IA): wherein each symbol is as defined in the specification. or a salt thereof or a prodrug thereof.